Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JAZZ PHARMACEUTICALS PLC

(JAZZ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Jazz Pharmaceuticals plc Announces National Comprehensive Cancer Network Adds Newly Approved Rylaze (Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn) to Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia

07/22/2021 | 04:15pm EDT

Jazz Pharmaceuticals plc announced that the National Comprehensive Cancer Network® (NCCN) added Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to the clinical practice guidelines in oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia (ALL), for both pediatric and adult patients. The NCCN guidelines for ALL and the NCCN guidelines for Pediatric ALL now include asparaginase erwinia chrysanthemi (recombinant)-rywn as a treatment option for patients with hypersensitivity to E. coli asparaginase products as a component of the multi-agent chemotherapeutic regimen to complete the full treatment course. Rylaze was approved by the U.S. Food and Drug Administration (FDA) on June 30, 2021 for use as a component of a multi-agent chemotherapeutic regimen given by intramuscular injection for the treatment of ALL and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase. The approval followed review of a Biologics Licensing Application under the FDA's Real-Time Oncology Review program, and it was based on clinical data from a pivotal phase 2/3 trial conducted in collaboration with the Children's Oncology Group.


© S&P Capital IQ 2021
All news about JAZZ PHARMACEUTICALS PLC
09/13JAZZ PHARMACEUTICALS : Announces Xywav® (calcium, magnesium, potassium, and sodi..
PR
09/08JAZZ PHARMACEUTICALS : to Participate in Upcoming September Investor Conferences
PR
09/08SK Biopharmaceuticals' New Drugs Draw Favorable Reception in North America, E..
MT
09/03KOSPI COMPOSITE INDEX : South Korean Stocks Close in Green on Foreign Buying Ahe..
MT
09/02SK Biopharmaceuticals Expands Overseas Market for Narcolepsy Drug to Canada
MT
09/02SK Biopharmaceuticals Rolls Out Narcolepsy Treatment Drug in Canada
MT
08/31JAZZ PHARMACEUTICALS : Announces Health Canada Approval of Sunosi® (solriamfetol..
AQ
08/31Jazz Pharmaceuticals plc Announces Health Canada Approval of Sunosi (solriamf..
CI
08/18JAZZ PHARMACEUTICALS : Corporate Overview
PU
08/16JAZZ PHARMACEUTICALS : HC Wainwright Adjusts Jazz Pharmaceuticals' Price Target ..
MT
More news
Analyst Recommendations on JAZZ PHARMACEUTICALS PLC
More recommendations
Financials (USD)
Sales 2021 3 087 M - -
Net income 2021 -383 M - -
Net Debt 2021 5 218 M - -
P/E ratio 2021 -17,3x
Yield 2021 -
Capitalization 8 057 M 8 057 M -
EV / Sales 2021 4,30x
EV / Sales 2022 3,29x
Nbr of Employees 1 940
Free-Float 97,5%
Chart JAZZ PHARMACEUTICALS PLC
Duration : Period :
Jazz Pharmaceuticals plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JAZZ PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 131,74 $
Average target price 207,82 $
Spread / Average Target 57,8%
EPS Revisions
Managers and Directors
Bruce C. Cozadd Chairman & Chief Executive Officer
Daniel N. Swisher President
Renée D. Galá Chief Financial Officer & Executive Vice President
Robert Iannone Chief Medical Officer, EVP-Research & Development
Finbar Larkin Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
JAZZ PHARMACEUTICALS PLC-20.18%8 146
JOHNSON & JOHNSON5.11%435 465
ROCHE HOLDING AG11.23%327 497
PFIZER, INC.21.46%251 011
NOVO NORDISK A/S49.16%231 607
ELI LILLY AND COMPANY38.43%211 895